Synairgen plc
$0.07
24H
Market Cap
Volume
Supply
Price Chart
About Synairgen plc - SNG.L
Synairgen plc is a biotechnology company focused on the development of respiratory drug candidates, specifically those targeting asthma, chronic obstructive pulmonary disease, and other lung conditions. They are known for their research on a broad-spectrum antiviral that targets a range of respiratory viruses.
What are Synairgen plc's core values and mission statement?
As of the last available information, Synairgen plc, a biotechnology company, focuses on the discovery and development of therapies for respiratory diseases, with a mission to build value through the innovation and development of therapeutics that address unmet needs in respiratory disease. Their core values emphasize scientific excellence, innovation, and partnership in advancing treatments for patients.
Who founded Synairgen plc and when?
Synairgen plc, a biotechnology company, was founded in 2003 by Professors Stephen Holgate, Donna Davies, and Ratko Djukanovic from the University of Southampton.
Who leads Synairgen plc?
As of the last update, Richard Marsden serves as the CEO of Synairgen plc.
Where is Synairgen plc located, and what is its base country?
Synairgen plc is based in Southampton, United Kingdom.
On which exchanges is Synairgen plc traded?
Synairgen plc's shares are traded on the AIM market of the London Stock Exchange.
Historical data
Synairgen plc (SNG) Price Live Data
The live price of Synairgen plc (SNG) is $0.07, with a trading volume of 191,136 in the last 24 hours. Wrapstocks updates the SNG price in real-time. Synairgen plc is down -3.13% in the last 24 hours. The company has a live market cap of $165,473.62 and a supply of 2,208,830 SNG stocks.
Synairgen plc (SNG) is traded on London Stock Exchange, and currently, the market is closed; trading will be resumed in 12 hours and 54 minutes.
